Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
A partir de données portant sur 82 patients atteints d'un cancer avancé du poumon non à petites cellules avec réarrangements du gène ALK et inclus dans un essai clinique de phase I, cette étude rétrospective évalue, par comparaison avec 356 autres patients, l'efficacité du crizotinib sur la survie
ALKgene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumour activity in patients with advanced, ALK-positive NSCLC. To assess whether crizotinib affects overall survival in these patients, we did a retrospective study comparing survival outcomes in crizotinib-treated patients in the trial and crizotinib-naive controls screened during the same time period. We examined overall survival in patients with advanced, ALK-positive NSCLC who enrolled in the phase 1 clinical trial of crizotinib, focusing on the cohort of 82 patients who had enrolled through Feb 10, 2010. For comparators, we identified 36 ALK-positive patients from trial sites who were not given crizotinib (ALK-positive controls), 67 patients withoutALKrearrangement but positive forEGFRmutation, and 253 wild-type patients lacking eitherALKrearrangement orEGFRmutation. To assess differences in overall survival, we assessed subsets of clinically comparable ALK-positive and ALK-negative patients. Among 82 ALK-positive patients who were given crizotinib, median overall survival from initiation of crizotinib has not been reached (95% CI 17 months to not reached); 1-year overall survival was 74% (95% CI 63?82), and 2-year overall survival was 54% (40?66). Overall survival did not differ based on age, sex, smoking history, or ethnic origin. Survival in 30 ALK-positive patients who were given crizotinib in the second-line or third-line setting was significantly longer than in 23 ALK-positive controls given any second-line therapy (median overall survival not reached [95% CI 14 months to not reached]vs6 months [4?17], 1-year overall survival 70% [95% CI 50?83]vs44% [23?64], and 2-year overall survival 55% [33?72]vs12% [2?30]; hazard ratio 0·36, 95% CI 0·17?0·75; p=0·004). Survival in 56 crizotinib-treated, ALK-positive patients was similar to that in 63 ALK-negative, EGFR-positive patients given EGFR TKI therapy (median overall survival not reached [95% CI 17 months to not reached]vs24 months [15?34], 1-year overall survival 71% [95% CI 58?81]vs74% [61?83], and 2-year overall survival 57% [40?71]vs52% [38?65]; p=0·786), whereas survival in 36 crizotinib-naive, ALK-positive controls was similar to that in 253 wild-type controls (median overall survival 20 months [95% CI 13?26]vs15 months [13?17]; p=0·244). In patients with advanced, ALK-positive NSCLC, crizotinib therapy is associated with improved survival compared with that of crizotinib-naive controls.ALKrearrangement is not a favourable prognostic factor in advanced NSCLC. Pfizer Inc, V Foundation for Cancer Research.
The Lancet Oncology , résumé, 2010